Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company anticipates that trading to begin on or about Aug. 5, 2021; the company will trade on the exchange using the … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American”
Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it received conditional listing approval from the NYSE American LLC stock exchange. The NYSE American is designed for growing companies and offers investors a variety of ways in which to trade. The exchange … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership”
Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment”
CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research organizations as part of those efforts, which include the transfer of its intellectual property assets to its recently formed wholly … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. (“TMS”). TMS is a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH), a group of 129 outpatient mental health service centers located across the … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Agreement with US Mental Health Chain Group”
CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution Report incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy”
